Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of Moderate Buy by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) has earned an average rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. […]

Related Keywords

United States ,Parkwood ,California ,America ,Samuelc Blackman ,Jeremy Bender ,Nasdaq ,Securities Exchange Commission ,Day One Biopharmaceuticals Inc ,Needham Company ,Day One Biopharmaceuticals ,Get Rating ,One Financial ,Exchange Commission ,Capital Management ,State Teachers Retirement System ,Rhumbline Advisers ,One Biopharmaceuticals ,Day One Biopharmaceuticals Daily ,Nasdaq Dawn ,Dawn ,Medical ,Ratings ,Consensus ,